PARP1 and neoplasm: Thus, a deficiency of ATR activity determines sensitivity to DNA damage agents such as IR, DNA cross-linking agents, and topoisomerase poisons [115]; its inhibition combined with PARP inhibitors also reduces tumor growth in BRCAness models [116] (Table 1).